Acurx Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-10-27$6.60 RISE2026-03-06$1.35 PEAK2026-03-19$6.63 143d | -79.5% 130d | Missed | Missed | — | — | +391.1% 13d | Missed |
DROP2025-06-17$16.42 RISE2025-09-04$3.86 PEAK2025-10-08$8.10 113d | -76.5% 79d | Missed | Missed | — | — | +109.8% 34d | Missed |
DROP2025-02-24$16.96 RISE2025-06-13$6.10 PEAK2025-06-17$16.42 113d | -64.0% 109d | Missed | Missed | — | — | +169.2% 4d | Missed |
DROP2024-11-25$26.40 RISE2025-04-08$6.10 PEAK2025-06-17$16.42 204d | -76.9% 134d | Missed | Missed | — | — | +169.2% 70d | Missed |
DROP2024-10-04$43.00 RISE2025-01-14$13.98 PEAK2025-01-21$17.80 109d | -67.5% 102d | Missed | Missed | — | — | +27.3% 7d | Missed |
DROP2024-05-21$55.80 RISE2024-09-24$36.60 PEAK2024-10-02$43.00 134d | -34.4% 126d | Missed | Missed | — | — | +17.5% 8d | Missed |
DROP2024-05-21$55.80 RISE2024-08-12$37.40 PEAK2024-08-21$46.60 92d | -33.0% 83d | Missed | Missed | — | — | +24.6% 9d | Missed |
DROP2024-02-26$65.00 RISE2024-07-03$40.20 PEAK2024-07-17$52.40 142d | -38.2% 128d | Missed | Missed | — | — | +30.3% 14d | Missed |
DROP2024-01-11$96.20 RISE2024-04-15$32.70 PEAK2024-05-21$55.80 131d | -66.0% 95d | Missed | Missed | — | — | +70.6% 36d | Missed |
DROP2023-10-18$115.20 RISE2024-02-13$56.00 PEAK2024-02-26$65.00 131d | -51.4% 118d | Missed | Missed | — | — | +16.1% 13d | Missed |
DROP2023-10-18$115.20 RISE2023-12-12$66.80 PEAK2024-01-11$96.20 85d | -42.0% 55d | Missed | Missed | — | — | +44.0% 30d | Missed |
DROP2023-10-18$115.20 RISE2023-11-06$65.40 PEAK2024-01-11$96.20 85d | -43.2% 19d | Missed | Missed | — | — | +47.1% 66d | Missed |
DROP2023-05-31$62.00 RISE2023-10-03$25.60 PEAK2023-10-18$115.20 140d | -58.7% 125d | Missed | Missed | — | — | +350.0% 15d | Missed |
DROP2023-04-05$70.60 RISE2023-08-15$32.00 PEAK2023-10-18$115.20 196d | -54.7% 132d | Missed | Missed | — | — | +260.0% 64d | Missed |
DROP2023-01-04$89.80 RISE2023-05-03$55.20 PEAK2023-05-15$67.80 131d | -38.5% 119d | Missed | Missed | — | — | +22.8% 12d | Missed |
1–15 / 23 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Moby summary of Acurx Pharmaceuticals, Inc.'s Q1 2026 earnings call
Acurx Pharmaceuticals (ACXP) beat Q1 2026 EPS estimates, reporting -$0.62 vs -$0.65, as it advances lead antibiotic ibezapolstat for C. diff and MRSA, with stock flat despite pre-market dip.
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDTCompany ParticipantsRobert Shawah - Co-Founder & CFODavid Luci -...
Presentation Operator MessageOperator Greetings, and welcome to the Acurx Pharmaceuticals First Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded....
STATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. , a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial...
DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activityNeutropenic CD-1 mice were infected intramuscularly with...
d Preclinical microbiome evaluation of novel PolC-inhibitor compounds Khurshida Begum1, Abdulwhab Shremo Msdi1, Chenlin Hu1, Neil Shaw, M Jahangir Alam1, Eugenie...
STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals , a fully-integrated biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial...
Acurx Pharmaceuticals, Inc. , a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it will be participating...
Acurx Pharmaceuticals Inc: Acurx Pharmaceuticals to discuss first quarter 2026 financial results on May 12, 2026 conference call and provide business update...
Acurx Pharmaceuticals Inc:Acurx Pharmaceuticals, Inc. announces closing of up to $7.1 million registered direct offering priced at-the-market under Nasdaq rules....
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
U.S. stocks higher, Dow up 100 points. NASDAQ and S&P 500 also see gains. Energy shares up, consumer discretionary down. Initial jobless claims decline.
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSTATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ --...
NEW YORK CITY, NY / ACCESS Newswire / April 4, 2026 / New to The Street, one of the longest-running U.S. and international business television brands, today announced the broadcast of Episode 741, airing tonight as sponsored programming on Bloomberg ...
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACXP | -8.33% | +29.41% | -20.48% | -74.55% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.30% | +35.13% | -17.04% | -87.24% |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-22 | Shawah Robert G. | Chief Financial Officer | A Grant / award(deriv) | 25,900 | — | +$0 |
| 2026-04-22 | LUCI DAVID P | President and CEO | A Grant / award(deriv) | 37,100 | — | +$0 |
| 2026-04-22 | DELUCCIA ROBERT J | Director | A Grant / award(deriv) | 37,100 | — | +$0 |
| 2026-04-22 | Scodari Joseph C | Director | A Grant / award(deriv) | 2,150 | — | +$0 |
| 2026-04-22 | HARRISON THOMAS L | Director | A Grant / award(deriv) | 2,150 | — | +$0 |
| 2026-04-22 | Donohue James J. | Director | A Grant / award(deriv) | 2,150 | — | +$0 |
| 2026-04-22 | DEAN JACK H | Director | A Grant / award(deriv) | 2,150 | — | +$0 |
| 2026-04-22 | Sailer Carl | Director | A Grant / award(deriv) | 2,150 | — | +$0 |
| 2025-02-06 | DELUCCIA ROBERT J | Director · 10% Owner | A Grant / award(deriv) | 250,000 | — | +$0 |
| 2025-02-06 | LUCI DAVID P | President and CEO | A Grant / award(deriv) | 250,000 | — | +$0 |
| 2025-02-06 | Shawah Robert G. | Chief Financial Officer | A Grant / award(deriv) | 145,500 | — | +$0 |
| 2025-01-08 | DEAN JACK H | Director | P Open-market purchase(deriv) | 9,852 | — | +$0 |
| 2025-01-08 | DEAN JACK H | Director | P Open-market purchase | 9,852 | $1.01 | +$10.0K |
| 2025-01-08 | DELUCCIA ROBERT J | Director · 10% Owner | P Open-market purchase(deriv) | 49,261 | — | +$0 |
| 2025-01-08 | DELUCCIA ROBERT J | Director · 10% Owner | P Open-market purchase | 49,261 | $1.01 | +$50.0K |
| 2025-01-08 | Donohue James J. | Director | P Open-market purchase(deriv) | 9,852 | — | +$0 |
| 2025-01-08 | Donohue James J. | Director | P Open-market purchase | 9,852 | $1.01 | +$10.0K |
| 2025-01-08 | LUCI DAVID P | President and CEO | P Open-market purchase(deriv) | 49,261 | — | +$0 |
| 2025-01-08 | LUCI DAVID P | President and CEO | P Open-market purchase | 49,261 | $1.01 | +$50.0K |
| 2025-01-08 | Sailer Carl | Director | P Open-market purchase(deriv) | 24,631 | — | +$0 |
| 2025-01-08 | Sailer Carl | Director | P Open-market purchase | 24,631 | $1.01 | +$25.0K |
| 2025-01-08 | Scodari Joseph C | Director | P Open-market purchase(deriv) | 24,631 | — | +$0 |
| 2025-01-08 | Scodari Joseph C | Director | P Open-market purchase | 24,631 | $1.01 | +$25.0K |
| 2024-06-18 | DEAN JACK H | Director | A Grant / award(deriv) | 12,000 | — | +$0 |
| 2024-06-18 | Donohue James J. | Director | A Grant / award(deriv) | 12,000 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | -0.43 | — | — |
| 2026-05-11 | -0.63 | -0.62 | +2.36% |
| 2026-03-12 | -1.01 | -0.31 | +69.31% |
| 2025-11-12 | -1.28 | -1.23 | +4.28% |
| 2025-08-11 | -2.10 | -1.89 | +10.00% |
| 2025-05-12 | -2.80 | -2.20 | +21.43% |
| 2025-03-17 | -3.60 | -3.20 | +11.11% |
| 2024-11-12 | -4.60 | -3.40 | +26.09% |
| 2024-08-08 | -5.60 | -5.20 | +7.14% |
| 2024-05-14 | -4.80 | -5.60 | -16.67% |
| 2024-03-15 | -4.90 | -7.60 | -55.10% |
| 2023-11-13 | -5.00 | -4.80 | +4.00% |
| 2023-08-11 | -4.60 | -5.60 | -21.74% |
| 2023-05-12 | -5.00 | -5.00 | — |
| 2023-03-15 | -6.20 | -5.60 | +9.68% |
| 2022-11-10 | -6.80 | -6.40 | +5.88% |